- Home
- MIN vs OLMA Comparison
MIN vs OLMA Comparison
Compare MIN & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIN
- OLMA
- Stock Information
- Founded
- MIN 1988
- OLMA 2006
- Country
- MIN United States
- OLMA United States
- Employees
- MIN N/A
- OLMA N/A
- Industry
- MIN Trusts Except Educational Religious and Charitable
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- MIN Finance
- OLMA Health Care
- Exchange
- MIN Nasdaq
- OLMA Nasdaq
- Market Cap
- MIN 304.4M
- OLMA 289.0M
- IPO Year
- MIN N/A
- OLMA 2020
- Fundamental
- Price
- MIN $2.68
- OLMA $5.28
- Analyst Decision
- MIN
- OLMA Strong Buy
- Analyst Count
- MIN 0
- OLMA 4
- Target Price
- MIN N/A
- OLMA $24.50
- AVG Volume (30 Days)
- MIN 331.0K
- OLMA 688.0K
- Earning Date
- MIN 01-01-0001
- OLMA 05-13-2025
- Dividend Yield
- MIN 7.31%
- OLMA N/A
- EPS Growth
- MIN N/A
- OLMA N/A
- EPS
- MIN 0.08
- OLMA N/A
- Revenue
- MIN N/A
- OLMA N/A
- Revenue This Year
- MIN N/A
- OLMA N/A
- Revenue Next Year
- MIN N/A
- OLMA N/A
- P/E Ratio
- MIN $33.38
- OLMA N/A
- Revenue Growth
- MIN N/A
- OLMA N/A
- 52 Week Low
- MIN $2.52
- OLMA $2.86
- 52 Week High
- MIN $2.88
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- MIN 51.79
- OLMA 60.00
- Support Level
- MIN $2.64
- OLMA $4.80
- Resistance Level
- MIN $2.68
- OLMA $5.61
- Average True Range (ATR)
- MIN 0.03
- OLMA 0.38
- MACD
- MIN -0.00
- OLMA 0.02
- Stochastic Oscillator
- MIN 66.67
- OLMA 78.71
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.